Le Lézard
Classified in: Health, Business
Subject: OTC

Moberg Pharma Publishes Information Document on the Proposed Divestment of the OTC-Business


STOCKHOLM, March 4, 2019 /PRNewswire/ -- On February 12th, 2019, it was announced that Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has entered into agreement with RoundTable Healthcare Partners and Signet Healthcare Partners to divest its entire commercial operations. Further information regarding the proposed divestment of the OTC-business has today been published and is available in the form of an information document.

The information document describes the proposed transaction as well as the Company's continued operations following a divestment of the OTC-business. The information document contains among other things financial pro forma information in the form of income statement and balance sheet for 2018, the background and reasons for the proposed divestment and detailed information regarding the different elements of the transaction.

The information document is only available in Swedish. However, the pro forma information is available in English in the form of a translation. The information document and the translation are available on the Company's website, http://www.mobergpharma.com/investors/calendarpresentations.

The published information document is to be used for information purposes only and as a basis for assessing the consequences of the proposed divestment of the OTC-business of Moberg Pharma and actions related thereto, which are described in the information document. The information document does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares or other securities in Moberg Pharma. The published information document has not been approved by any regulatory authority and is not a prospectus.

CONTACT:

For additional information, please contact: 

Peter Wolpert, CEO
phone: Sweden: +46-707-35-7135
US: +1-908-432-2203
e-mail: [email protected] 

Anna Ljung, CFO
phone: +46-707-66-6030
e-mail: [email protected]

About this information              

The information was submitted for publication, through the contact persons set out above, at 8.30 a.m. (CET) on March 4th, 2019. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/moberg-pharma/r/moberg-pharma-publishes-information-document-on-the-proposed-divestment-of-the-otc-business,c2754647

The following files are available for download:

https://mb.cision.com/Main/1662/2754647/1001269.pdf

Moberg Pharma publishes information document on the proposed divestment of the OTC-business

https://mb.cision.com/Public/1662/2754647/8e8cb28e00e70b68.pdf

Information Document 190304

https://mb.cision.com/Public/1662/2754647/bf31d1f4c6b720ad.pdf

English translation of pro forma 190304

SOURCE Moberg Pharma


These press releases may also interest you

at 19:19
With recent news of dairy cattle in the United States testing positive for the Highly Pathogenic Avian Influenza (HPAI) and reports of fragments of HPAI detected in pasteurized milk sold in the U.S., we understand that Canadians may be concerned...

at 19:01
Butterfly Medical Ltd, an early-stage medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), is excited to announce the hiring of Patrick MacCarthy as CEO. ...

at 18:33
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of...

at 18:29
Filament Health Corp. (Cboe CA: FH) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors...

at 18:20
Starting this week, National Alliance for Hispanic Health, Ibero American Action League Inc., University of Rochester Medical Center, and Trillium Health in Rochester, NY will host the All of Us Journey, a traveling educational exhibit that brings...

at 18:00
BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to...



News published on and distributed by: